NPPB and cancer: Furthermore, even before cardiotoxic treatment, cancer patients can have elevated NT-proBNP (defined as NT-proBNP > 125 pg/mL) levels, which is significantly associated with all-cause mortality, highlighting the interplay between subclinical cardiac dysfunction with cancer progression [36].